Imatinib

Drug Profile

Imatinib

Alternative Names: CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Acute lymphoblastic leukaemia; Dermatofibrosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Systemic mastocytosis
  • Phase II Acute myeloid leukaemia; Fibroma; Non-Hodgkin's lymphoma; Prostate cancer
  • No development reported Malignant melanoma; Mesothelioma
  • Discontinued Diffuse scleroderma; Glioblastoma; Non-small cell lung cancer; Polycythaemia vera; Pulmonary arterial hypertension; Sarcoma; Small cell lung cancer; Systemic scleroderma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mesothelioma(Inoperable/Unresectable, Metastatic disease) in USA (PO)
  • 12 Jul 2017 Novartis completes a phase III trial in Gastrointestinal stromal tumours (Adjuvant therapy) in Germany, Denmark, United Kingdom, Spain, Italy, Australia and France (PO) (NCT00103168) (EudraCT2004-001810-16)
  • 02 Jun 2017 Adverse events and efficacy data from the phase-II PERSIST-5 trial in Gastrointestinal stromal tumours (Adjuvant therapy) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top